FDA shall
continue to work with the regulated community to seek ways to
integrate and streamline its adverse event reporting systems to the
extent that such changes can improve and simplify reporting. FDA
shall take care to work closely with interested parties who would
be affected by any changes and will subject any redesigns to public
comment prior to OMB submission.
Inventory as of this Action
Requested
Previously Approved
04/30/2003
04/30/2003
04/30/2001
332,414
0
328,361
332,414
0
320,081
0
0
0
Reporting of adverse events and
product problems by health professionals to the FDA either directly
or via the manufacturer is critical to an effective national
postmarketing surveillance system. The overall MedWatch program is
a national educational/ promotional initiative designed both to
educate all health professionals about the critical importance of
being aware of, monitoring for, and reporting adverse events and
problems to FDA and/or the manufacturer, and to ensure that new
medical product safety information is rapidly communicated to the
health professional community, thereby improving patient
care.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.